Outcomes of patients with aggressive B-cell non-Hodgkin s lymphoma who undergo hematopoietic cell transplantation after CAR T-cell therapy Read more
Tafasitamab, Lenalidomide and Venetoclax Combination Therapy for Relapsed or Refractory Mantle Cell Lymphoma (V-MIND): A Phase II Study with Safety Lead-in Read more
A randomized, open-label study evaluating the efficacy and safety of cemacabtagene ansegedleucel in participants with minimal residual disease after response to first line therapy for large B-cell lymphoma ALPHA3) Read more
Outcomes among Adult Recipients of CAR T-Cell Therapeutics for Burkitt and Burkitt-like Lymphoma Read more
Outcomes of Patients with Relapsed/Refractory Hodgkin Lymphoma Treated with PD-1 Inhibitors Outside of Clinical Trials Read more
A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) Read more
Outcomes of Patients with Newly Diagnosed Peripheral T-cell Lymphoma Treated with Aggressive Chemotherapy, including Cutaneous Gamma-Delta T cell Lymphoma Read more
